{
    "id": "06d1f3a6-8673-4789-9a7f-3cc17cda4fed",
    "indications": {
        "text": "risperidone atypical antipsychotic indicated : treatment schizophrenia ( 1.1 ) monotherapy adjunctive therapy lithium valproate , treatment acute manic mixed episodes associated bipolar 1 disorder ( 1.2 ) treatment irritability associated autistic disorder ( 1.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "table 1. recommended daily indication initial dose titration ( increments ) target dose effective dose range schizophrenia : adults ( 2.1 ) 2 mg 1 2 mg 4 8 mg 4 16 mg schizophrenia : adolescents ( 2.2 ) 0.5 mg 0.5 mg 1 mg 3 mg 1 6 mg bipolar mania : adults ( 2.2 ) 2 3 mg 1 mg 1 6 mg 1 6 mg bipolar mania : children adolescents ( 2.2 ) 0.5 mg 0.5 mg 1 mg 1 2.5 mg 1 6 mg irritability autistic disorder ( 2.3 ) 0.25 mg increase 0.5 mg day 4 : ( body weight less 20 kg ) 0.5 mg increase 1 mg day 4 : ( body weight greater equal 20 kg ) . day 4 , intervals > 2 weeks : 0.25 mg ( body weight less 20 kg ) 0.5 mg ( body weight greater equal 20 kg ) 0.5 mg : ( body weight less 20 kg ) 1 mg : ( body weight greater equal 20 kg ) 0.5 3 mg severe renal hepatic impairment adults : lower starting dose 0.5 mg twice daily . may increase dosages 1.5 mg twice daily intervals one week longer .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal hepatic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_42738"
            }
        ]
    },
    "adverseReactions": "risperidone contraindicated patients known hypersensitivity either risperidone paliperidone , excipients resperidone formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "ingredients": [
        {
            "name": "RISPERIDONE",
            "code": "L6UH7ZF8HC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        },
        {
            "name": "ASPARTAME",
            "code": "Z0H242BBR1",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2877"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "organization": "Endo USA, Inc.",
    "name": "Risperidone",
    "effectiveTime": "20240730",
    "indications_original": "Risperidone is an atypical antipsychotic indicated for: Treatment of schizophrenia (1.1) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar 1 Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 )",
    "contraindications_original": "Table 1. Recommended Daily Dosage by Indication\n                  \n                  \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \u00a0\n                           \u00a0\n            \n                                 \u00a0Initial Dose\n                                 \n                              \n                           \n                           \u00a0\n            \n                                 Titration (Increments)\n                              \n                           \n                           \u00a0\n            \n                                 Target Dose\n                              \n                           \n                           \u00a0\n            \n                                 Effective Dose Range\n                              \n                           \n                        \n                        \n                           \u00a0\n            \n                                 \u00a0Schizophrenia: adults (2.1)\n                                 \n                              \n                           \n                           \u00a0\n            \n                                 \u00a02 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a01 to 2 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a04 to 8 mg\n                              \n                           \n                           \u00a0\n            4 to 16 mg\n                           \n                        \n                        \n                           \u00a0\n            \n                                 \u00a0Schizophrenia: adolescents (2.2)\n                                 \n                              \n                           \n                           \u00a0\n            \n                                 \u00a00.5 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a00.5 mg to 1 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a03 mg\n                              \n                           \n                           \u00a0\n            1 to 6 mg\n                           \n                        \n                        \n                           \u00a0\n            \n                                 \u00a0Bipolar mania: adults (2.2)\n                                 \n                              \n                           \n                           \u00a0\n            \n                                 \u00a02 to 3 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a01 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a01 to 6 mg\n                              \n                           \n                           \u00a0\n            1 to 6 mg\n                           \n                        \n                        \n                           \u00a0\n            \n                                 \u00a0Bipolar mania: children and adolescents (2.2)\n                                 \n                              \n                           \n                           \u00a0\n            \n                                 \u00a00.5 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a00.5 mg to 1 mg\n                              \n                           \n                           \u00a0\n            \n                                 \u00a01 to 2.5 mg\n                              \n                           \n                           \u00a0\n            1 to 6 mg\n                           \n                        \n                        \n                           \u00a0\n            \n                                 \n                                    Irritability in autistic disorder (2.3)\n                                 \n                              \n                           \n                           \u00a0\n            0.25 mg Can increase to 0.5 mg by Day 4: (body weight less than 20 kg)\n                              0.5 mg Can increase to 1 mg by Day 4: (body weight greater than or equal to 20 kg).\n                           \n                           \n                              After Day 4, at intervals of >2 weeks: 0.25 mg (body weight less than 20 kg)\n                              0.5 mg (body weight greater than or equal to 20 kg)\n                           \n                           \u00a0\n            0.5 mg: (body weight less than 20 kg)\n                              1 mg: (body weight greater than or equal to 20 kg)\n                           \n                           \u00a0\n            0.5 to 3 mg\n                           \n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "adverseReactions_original": "Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the resperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.",
    "drug": [
        {
            "name": "Risperidone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        }
    ]
}